Original article
CNVs affecting cancer predisposing genes (CPGs) detected as incidental findings in routine germline diagnostic chromosomal microarray (CMA) testing AbsTrACT background identification of cnVs through chromosomal microarray (cMa) testing is the first-line investigation in individuals with learning difficulties/ congenital abnormalities. although recognised that cMa testing may identify cnVs encompassing a cancer predisposition gene (cPg), limited information is available on the frequency and nature of such results. Methods We investigated cnV gains and losses affecting 39 cPgs in 3366 pilot index case individuals undergoing cMa testing, and then studied an extended cohort (n=10 454) for cnV losses at 105 cPgs and cnV gains at 9 proto-oncogenes implicated in inherited cancer susceptibility. results in the pilot cohort, 31/3366 (0.92%) individuals had a cnV involving one or more of 16/39 cPgs. 30/31 cnVs involved a tumour suppressor gene (tSg), and 1/30 a proto-oncogene (gain of MET). BMPR1A, TSC2 and TMEM127 were affected in multiple cases. in the second stage analysis, 49/10 454 (0.47%) individuals in the extended cohort had 50 cnVs involving 24/105 cPgs. 43/50 cnVs involved a tSg and 7/50 a proto-oncogene (4 gains, 3 deletions). the most frequently involved genes, FLCN (n=10) and SDHA (n=7), map to the Smith-Magenis and cri-du-chat regions, respectively. Conclusion incidental identification of a cnV involving a cPg is not rare and poses challenges for future cancer risk estimation. Prospective data collection from cPg-cnV cohorts ascertained incidentally and through syndromic presentations is required to determine the risks posed by specific cnVs. in particular, ascertainment and investigation of adults with cPg-cnVs and adults with learning disability and cancer, could provide important information to guide clinical management and surveillance.
InTroduCTIon
The human genome contains marked structural variation and it is over 10 years since the first comprehensive CNV map of the human genome was published.
1 For children presenting with developmental delay/learning difficulties and/or congenital abnormalities, diagnostic germline chromosomal microarray (CMA) for causative CNVs is now a first-line investigation and, together with advances in CMA technology leading to improving resolution, 2 there are increasingly numbers of patients identified with CNVs of uncertain significance or for which the resulting phenotype is unclear. This is particularly pertinent where an identified CNV encompasses an inherited cancer predisposition gene (CPG) and there is no relevant personal or family history, a so-called incidental finding.
With the mainstreaming of modern genomic investigations, CMA testing is often ordered by non-genetics healthcare professionals (eg, paediatricians) who may have limited familiarity with familial cancer syndromes and are unable to advise on the full significance of the CMA result. Previously, Pichert et al 3 described the frequency of CNVs affecting 47 CPGs in 4805 CMA analyses. We report an independent replication study on a larger patient cohort (twofold increase in cases and a more extensive CPG list (n=105).
MeThods

Participants and samples
Samples were referred by paediatricians and clinical geneticists where constitutional diagnostic array comparative genomic hybridisation (aCGH) was requested to determine causes of developmental delay, learning difficulties, neurocognitive impairment and/or birth defects. Only arrays pertaining to the index case in a family were included. The following were excluded: (i) patients with clinical features and/or a family history suggestive of the involvement of a known CPG; (ii) samples from prenatal diagnoses; (iii) results involving whole chromosome or chromosome arm aneuploidy and (iv) results where the CNV identified involving a CPG was present in mosaic form. Monozygotic twins were counted as one individual for the purposes of this study. A finding was considered positive where the involvement of a CPG was not suspected before testing (ie, an incidental finding). CNVs included in the results were those where the CNV was considered to be causative of the index case's presenting features, and also CNVs of either benign or uncertain significance. Approval for the clinical audit study was provided by Birmingham Women's NHS Foundation Trust and Central Manchester University Hospitals NHS Foundation Trust. 
Cancer genetics
Gene search lists
The pilot cohort (n=3366) was analysed for CNV gains and losses involving a core set of 39 genes (4 oncogenes, 35 tumour suppressor genes) associated with familial cancer predisposition syndromes (see online supplementary table S1). In the 10 k extended cohort (10 454 [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Additionally, in the 10 k extended cohort, CNV gains at 9 of the105 genes (ALK, EGFR, HRAS, RHBDF2, CDK4, KIT, MET, PDGFRA, RET) 10 16-23 were investigated as activating alterations have been described in hereditary cancer predisposition. Partial or whole gene losses and gains were noted and counted as positive findings.
Laboratory methods and bioinformatics analysis
Testing was undertaken in CPA-accredited laboratories. aCGH analysis was carried out using DNA extracted from peripheral blood or mouthwash samples using standard techniques.
For the pilot cohort, aCGH was carried out using either the BlueGnome CytoChip 1 Mb BAC (Bacterial Artificial Chromosome) array or the Bluegnome 8×60k V.2.0 (ISCA) design oligonucleotide array. aCGH data analysis was performed using BlueFuse Multi software. CNV detection using the Bluegnome 1 Mb BAC array was carried out with a successful BAC inclusion threshold of >95%. Single clones were called as CNVs using Log2 thresholds of ±0.3. CNV detection using the Bluegnome 8×60k v2.0 (ISCA) design oligonucleotide array was carried out with a minimum three probe inclusion using Log2 ratio thresholds of ±0.3. No minimum size threshold was applied for either platform.
For the 10 k extended cohort, aCGH testing was carried out using Oxford Gene Technology (OGT) CytoSureTM ISCA v2 (8×60 k) arrays for all cases with the exception of P102 which was tested using OGT CytoSureTM Constitutional V.3 Array (8×60 k). aCGH data analysis was performed using Figure 1 Percentage of cnVs detected in the stage 1 pilot cohort affecting the cancer predisposition gene (cPg) shown and whether the cnVs detected were gains or deletions. Where a cPg gene present in online supplementary table S1 is not shown, then no cnV involving it was detected.
OGT CytoSure Interpret software. CNV detection was based on a minimum four probe inclusion using Log2 thresholds of ≥0.35 for gains and ≤−0.6 for losses, and no minimum size threshold applied.
For both studies, automatically called CNVs were subject to manual assessment to exclude artefacts and a manual screen for mosaic aberrations was also performed. Inheritance studies were performed using karyotype analysis, targeted aCGH or in situ hybridisation studies, as appropriate where parental samples were available.
CNV coordinates described are based on the minimum affected region as per standard practice and all coordinates are GRCh37/hg19 except where otherwise stated.
statistical analysis
Age data is calculated as mean, SEM, range and median. The 'incidental finding' rate was 0.92% (31/3366). Mean age at CNV analysis in individuals with a positive finding was 51.9 months (SEM 14.2, range 0-312 months, median 8 months). In 16/31 cases, the CPG-related CNV was considered to be relevant to the clinical phenotype and in 15 individuals the CNV identified was considered to be either unrelated or of uncertain clinical significance. In 10 cases, the CNV encompassing the cancer gene was de novo and in 14 cases the CNV was inherited (including one where the child inherited the unbalanced form of a parental balanced translocation). The family history was known in 11 of the 14 cases where the CNV was inherited (excluding the case with the unbalanced form of the parental translocation), and there were no clinical features in keeping with a germline pathogenic alteration of the CPG.
Only one of the CNVs involved an oncogene, a gain encompassing MET. supplementary table S1 and  table S3 ). The mean age at aCGH in individuals with a positive finding was 87.5 months (SEM 15.0, range 0-460 months, median 46.5 months). In 40 individuals, the array finding involving the cancer gene was thought to be causative of the clinical phenotype in the index individual and in 9 cases the CNV identified was of uncertain clinical significance or unrelated to the presenting features. In 27 cases, the CNV arose de novo and in 6 cases the CNV was inherited. In three of these six cases, the child had inherited the unbalanced form of a parental balanced translocation. In the remaining three cases, the family history was known in two cases and there were no clinical features in keeping with a germline pathogenic alteration of the CPG.
Seven of the 50 CNVs involved an oncogene: 4 gains (HRAS x2, MET and PDGFRA) and 3 deletions (METx2, one involving both KIT/PDGFRA). The remaining 43 CNVs were deletions involving TSGs. In one case, there was a heterozygous contiguous deletion of two TSGs (BLM and FANCI). Four of the CNVs (in three individuals) arose as a consequence of complex chromosomal rearrangement resulting in gain of an oncogene in three cases (HRAS x2, MET x1) and loss of a tumour suppressor gene (SDHA) in one. These 50 CNVs affected 24 of the 105 genes on the search list (24/105=22.9%) with CNVs affecting FLCN accounting for 10/50 (20%) and of SDHA 7/50 (14%) (figure 2).
Joint analysis of stage 1 and stage 2 datasets and CPG lists
Oncogene gains: 3 of 13 820 cases (0.02%) in the combined stage 1 and stage 2 cohorts had a CNV gain at one or more of the four oncogenes (RET, PDGFRA, MET and KIT) in the stage 1 gene list with CNV gains occurring twice at the MET locus (including one individual with a complex rearrangement leading to gain) and once at the PDGFRA locus. Three individuals had a deletion of one or more of these oncogenes (including the one individual with the deletion of both MET and PDGFRA and two with a deletion of MET) (see online supplementary table S4).
TSG losses: 30 of 13 820 (0.22%) individuals in the combined stage 1 and 2 cohorts had a partial or whole deletion involving one or more of 35 tumour suppressor genes (see online supplementary table S4). In 22/30 cases, the CNV identified was thought to be causative of the child's presenting features and was thought to be either unrelated to, or of uncertain significance, in the remaining eight. In 17 cases, the CNV identified was de novo and was found to be inherited in six individuals (including one where the child had inherited the unbalanced form of the parental balanced translocation). Fifteen of the 39 (38.5%) genes on the common search list (12 tumour suppressor genes and 3 oncogenes) were affected by a deletion CNV with SDHA being involved in 9 CNVs and BMPR1A in 6 CNVs (figure 3) (see online supplementary table S4).
CnVs encompassing CPGs residing within the known chromosomal microdeletion regions: 17 p11.2 and 5 p15.22
Ten individuals (stage 2 cohort) had a CNV encompassing FLCN (chr17: 17 115 527-17 140 502) which resides within the Smith-Magenis syndrome (SMS) region on 17p11.2 (Decipher chr17: 16 773 072-20 222 149), 24 accounting for 20% of the total CNVs identified ( figure 2, figure 4) . Five of the CNVs were known to be de novo and in five the inheritance was unknown. In four individuals (P113, P111, P116, P119), the majority of the CNV overlapped with but did not encompass the SMS region. In the remaining six, the SMS region was contained within the CNV.
Nine individuals (two from stage 1 and seven from stage 2) had a deletion encompassing SDHA (chr5: 2 18 356-2 56 814), which resides towards the 5' end of the cri-du-chat region (Decipher chr5: 10 001-12 533 304) 24 accounting for 26.0% of the total number of CNVs identified in the combined cohorts ( figure 3, figure 5 ). In five individuals the CNV was within the cri-du-chat region and, in the remaining four, the CNV identified extended 3' beyond the critical region (figure 5). The CNV was inherited in three individuals (including the individual with the unbalanced translocation leading to loss of SDHA and gain of HRAS), de novo in two and inheritance was unknown in four individuals.
dIsCussIon
CMA testing is now routinely ordered for individuals presenting with undiagnosed learning difficulties and/or developmental abnormalities and is often undertaken outwith the genetics clinic, for example, in the paediatric mainstream setting.
While these investigations provide the opportunity for diagnosis, the CNVs identified may encompass or involve genes where intragenic alteration or whole gene copy number losses are known to be associated with predisposition to other condition(s) unrelated to the presenting features and can be classed as incidental findings. Unlike other genome-wide molecular genetic diagnostic strategies, such as whole exome and genome sequencing for which results can be filtered in a gene-specific manner, identified CNVs are usually visible to the investigator. 
Cancer genetics
Incidental finding CNVs involving CPGs can present significant counselling challenges as (1) while the phenotype and cancer risks of intragenic mutations in a CPG may be well defined the risks associated with large CNVs are often unclear as deletion of additional in cis genes might modify cancer risks 25 ; (2) the known cancer risks associated with CPGs are for individuals ascertained because of a family history and are likely to be lower for population-based ascertainment and (3) most CNVs involved CPGs associated with later-onset cancers, whereas CMA is more commonly performed in a paediatric setting (mean age at positive finding in our pilot and extended cohorts was 51.9 and 87.5 m, respectively). Nevertheless, CPG-CNVs cannot be ignored-as exemplified by two infants (P136 and P137, ages at aCGH 0 and 3 m, respectively) with deletions of ~50 and 24.5 Mb, respectively encompassing RB1 who subsequently developed clinical retinoblastoma after the CMA was requested. While retinoblastoma is highly penetrant at a young age (mean age diagnosis of bilateral retinoblastoma 15 m), 26 and the tumour penetrance for intragenic mutation of other CPGs is often more variable, this highlights that CNVs encompassing a CPG may be of clinical consequence and should be considered as a paradigm for the need to report such findings until more is known regarding their effects.
Indeed, recent analysis of a range of CPGs showed that large deletions including whole gene deletions were associated with fairly typical cancer predisposition compared with point mutations. 27 Deletions of CPGs with substantial childhood-onset risks such as SMARCB1 (malignant rhabdoid tumour) and TP53 (brain and sarcoma) also appear to be not infrequent and there is no evidence these deletions are less penetrant than point mutations. 27 On the other hand, we also detected an inherited deletion encompassing BMPR1A (P005), where there was no family history of polyposis. While BMPR1A mutations are of lower penetrance than RB1, 28 it likely that other factors influencing penetrance/expression are also involved. Varying phenotypic consequences of large deletions encompassing disease-causing genes are a recognised challenge 29 and the mechanisms underlying such variable phenotypic effects may include combinations of underlying genomic architecture, long range regulatory effects and, more recently recognised, the influence of topology associated domains. 30 In addition, for CNVs involving TSGs the somatic 'second hit' might result in homozygous loss of many genes in the cancer cell and result in non-viability through loss of an essential gene or by producing, in combination with loss of the CPG, a synthetic lethal state. 31 In four individuals, we identified partial deletions of a TSG. While with CMA it is not possible to precisely characterise the breakpoints, we would expect multi-exon deletions to be pathogenic, particularly where they have been described in the corresponding familial cancer syndrome. [32] [33] [34] [35] However, in these partial deletion cases we cannot exclude the possibility of expression of an abnormally truncated gene product, although one patient, (P029), did subsequently develop features of tuberous sclerosis indicating pathogenicity. For CNVs resulting in the gain of a TSG or proto-oncogene, the phenotypic consequences can also be very difficult to interpret. CMA gives no positional information (other than where there is also a cytogenetically characterised complex rearrangement, as occurred in eight individuals) and a CMA-detected copy number gain might be caused by an intragenic duplication that inactivated a TSG or gain of a functional proto-oncogeneeither of which might be associated with a cancer risk.
The CPGs most commonly involved in CNVs were SDHA and FLCN and both reside within the chromosomal microdeletion regions for cri-du-chat (Decipher chr5: 10 001-12 533 304) and Smith-Magenis (Decipher chr17: 16 773 072-20 222 149), respectively. 24 36 37 Although towards the 5' end, SDHA is within the cri-du-chat deleted region which has an incidence of 1:15 000-1:50 000. 38 Intragenic SDHA inactivating mutations may be associated with phaeochromocytoma, paraganglioma and gastrointestinal stromal tumours. 15 39 Although the penetrance of familial SDHA mutations has been estimated at ~40% by age 40 years, 40 other evidence suggests that the penetrance is much lower 39 and to date we are not aware of any SDHA-related tumours reported in patients with cri-du-chat. 41 Nevertheless, subject to appropriate ethical considerations, it would be of interest to investigate adults with cri-du-chat deletions involving SDHA for subclinical evidence of SDHA-related tumours.
FLCN lies within the SMS region on 17p11.2 and accounted for 20% of the CNVs identified. Germline mutations in FLCN cause Birt-Hogg-Dube (BHD) syndrome, which is characterised by the appearance of fibrofolliculomas from the third decade and renal cell carcinoma in about 25%-30% of cases. 42 RCC has been described in patients with SMS, 43 but the precise risk of RCC in patients with SMS with FLCN loss is unclear and further information is required to determine whether surveillance for RCC should be offered routinely. Nevertheless, in the presence of lung cysts or fibrofolliculomas (which on average precede RCC in BHD syndrome), it would seem prudent to do so.
Our CNV detection rate encompassing a CPG was between 0.3% (stage 1 and 2 combined, n=13 820) and 1% (stage 1 pilot, n=3366) in individuals undergoing diagnostic CMA. Pichert et al found CNVs affecting CPGs in 0.6% of 4805 diagnostic arrays and Boone et al 44 detected 0.9% in 9005 arrays, although this study involved a search list of 40 genes involved in adultonset disorders not specifically focused towards cancer genes.
This study is the largest to date of CNVs affecting CPGs detected as incidental findings has demonstrated that optimal management of incidentally detected CPG-CNVs and will require systematic collection of long-term follow-up data and international data sharing. In particular, detailed studies of the clinical significance of SDHA and FLCN loss in patients with cri-du-chat and SMS would address the most frequently detected CPG-CNVs. Although CMAs are routinely performed in children with learning disability, significant numbers of adults with learning disability are likely not to have had high-resolution CMA testing and routine reinvestigation of such patients could provide important information on cancer risks. In addition, we are compiling a database of adults with pathogenic CNVs and cancer and request that appropriate cases should be notified to Emma. Woodward@ cmft. nhs. uk.
